Metformin / Hif1a Cancer Research Results

MET, Metformin: Click to Expand ⟱

Features: oral antidiabetic agent,

Metformin is a pleiotropic drug: attributed to its action on AMPK
Metformin is a biguanide drug used primarily for type 2 diabetes. Mechanistically, it is best described as a bioenergetic modulator: partial inhibition of mitochondrial respiration can raise AMP/ADP, engage AMPK, and suppress mTORC1 signaling; systemically it reduces hepatic gluconeogenesis and can lower insulin/IGF-1 growth signaling. In oncology, observational studies suggested improved outcomes in some settings, but randomized trial data are mixed (e.g., large adjuvant breast cancer data did not show broad benefit overall). Long-term use can be associated with vitamin B12 deficiency, and prescribing requires attention to renal function due to rare lactic acidosis risk in predisposed states.
Metformin directly(partially) inhibits Complex I of the electron transport chain (ETC) in mitochondria. This inhibition decreases mitochondrial ATP production and forces cells to rely more on glycolysis for energy.
Cancer cells, especially those with high energy demands, may be particularly sensitive to a drop in ATP levels. The inhibition of Complex I also increases the AMP/ATP ratio, setting the stage for the activation of downstream energy stress pathways.
AMPK activation results in the inhibition of the mammalian target of rapamycin (mTOR) pathway, a central regulator of protein synthesis and cellular growth. mTOR inhibition reduces cell proliferation and limits tissue growth, which can slow tumor progression.

Metformin reduces circulating insulin levels, which in turn can decrease the activation of the insulin and insulin-like growth factor-1 (IGF-1) receptor pathways.

ETC Inhibitors: Drugs that directly inhibit specific ETC complexes (e.g., Complex I inhibitors like metformin or phenformin) can increase electron leakage and ROS production.(dose- and context-dependent, and not consistent)

-known as mild OXPHOS inhibitor(Complex I modulator)

Rank	Pathway / Axis	Cancer / Tumor Context	Normal Tissue Context	TSF	Primary Effect	Notes / Interpretation
1	Mitochondrial Complex I (OXPHOS) inhibition	Energetic stress ↑; proliferation pressure ↓ (context)	Hepatic energy shift; gluconeogenesis ↓	P, R	Bioenergetic modulation	Metformin partially inhibits mitochondrial Complex I (OXPHOS), increasing AMP/ADP ratio and triggering downstream AMPK activation. ROS changes are dose- and context-dependent.
2	AMPK activation (LKB1/AMPK axis)	Growth programs ↓ (context-dependent)	Metabolic homeostasis ↑	R	Energy-sensor activation	AMPK activation is frequently invoked downstream of respiratory inhibition, though some hepatic effects can be AMPK-independent.
3	mTORC1 inhibition (via AMPK→TSC2/Raptor; also AMPK-independent routes reported)	Protein synthesis / growth signaling ↓ (reported)	Reduced anabolic signaling in liver (context)	R, G	Anti-anabolic signaling	Mechanistically supported: AMPK regulation of TSC2 and Raptor contributes to metformin-mediated mTORC1 inhibition; AMPK-independent mTORC1 inhibition has also been described.
4	Hepatic gluconeogenesis suppression	Indirect tumor support via insulin/IGF-1 lowering (systemic)	Liver glucose production ↓ (core clinical effect)	R, G	Systemic metabolic effect	Metformin reduces hepatic glucose output through multiple mechanisms (energy state shifts, cAMP pathways, and other proposed nodes).
5	Insulin / IGF-1 axis (systemic growth signaling)	Mitogenic tone ↓ (context; strongest in hyperinsulinemic settings)	Insulin sensitivity ↑; insulin levels ↓ (context)	G	Systemic growth-factor modulation	Many “anti-cancer” hypotheses depend on lowering insulin/IGF-1 signaling rather than direct tumor cytotoxicity.
6	Cell-cycle & apoptosis (secondary, model-dependent)	Proliferation ↓; apoptosis ↑ (reported in some models)	↔	G	Conditional cytostasis	Often downstream of mTORC1 suppression/energy stress; not a universal direct cytotoxin signature.
7	Inflammation signaling (NF-κB and related programs)	Inflammatory pro-survival transcription ↓ (reported)	Anti-inflammatory trends in metabolic disease contexts	R, G	Inflammation modulation	Frequently reported as downstream of improved metabolic/oxidative stress tone; avoid presenting as a primary direct target.
8	Autophagy / stress adaptation	Autophagy ↑ or ↓ depending on context; can affect therapy response	↔	G	Adaptive stress response	Autophagy findings are heterogeneous across tumor models and combinations.
9	Clinical oncology evidence (adjunct use)	Observational signals exist; randomized data are mixed	—	—	Translation constraint	Epidemiology/meta-analyses suggested potential benefit in some cancers, but large randomized trials (e.g., adjuvant breast cancer MA.32) did not show broad benefit across the overall population.
10	Safety / monitoring constraints (B12, lactic acidosis risk in predisposed states)	—	Vitamin B12 deficiency risk with long-term use; rare lactic acidosis risk increases with renal impairment and other conditions	—	Clinical risk management	Long-term B12 monitoring is commonly advised; prescribing requires renal function assessment due to lactic acidosis risk in predisposed settings.

Time-Scale Flag (TSF): P / R / G

P: 0–30 min (rapid bioenergetic effects)
R: 30 min–3 hr (acute signaling shifts: AMPK/mTOR)
G: >3 hr (gene-regulatory adaptation and phenotype outcomes)

Hif1a, HIF1α/HIF1a: Click to Expand ⟱

Source:

Type:

Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product)
-Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells
-HIF1A induces the expression of vascular endothelial growth factor (VEGF)
-High HIF-1α expression is associated with Poor prognosis
-Low HIF-1α expression is associated with Better prognosis

-Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism.
-Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis

Key mediators of aerobic glycolysis regulated by HIF-1α.
-GLUT-1 → regulation of the flux of glucose into cells.
-HK2 → catalysis of the first step of glucose metabolism.
-PKM2 → regulation of rate-limiting step of glycolysis.
-Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis.
-LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate;

HIF-1α Inhibitors:
-Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate).
-Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions.
-EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity.
-Emodin: reduce HIF-1α expression. (under hypoxia).
-Apigenin: inhibit HIF-1α accumulation.

Scientific Papers found: Click to Expand⟱

1640-

CA,

MET,

Caffeic Acid Targets AMPK Signaling and Regulates Tricarboxylic Acid Cycle Anaplerosis while Metformin Downregulates HIF-1α-Induced Glycolytic Enzymes in Human Cervical Squamous Cell Carcinoma Lines

in-vitro,

Cerv,

SiHa

GLS↓, NADPH↓, ROS↑, TumCD↑, AMPK↑, Hif1a↓, GLUT1↓, GLUT3↓, HK2↓, PFK↓, PKM2↓, LDH↓, cMyc↓, BAX↓, cycD1/CCND1↓, PDH↓, ROS↑, Apoptosis↑, eff↑, ACLY↓, FASN↓, Bcl-2↓, Glycolysis↓,

1866-

DCA,

MET,

BTZ,

Targeting metabolic pathways alleviates bortezomib-induced neuropathic pain without compromising anticancer efficacy in a sex-specific manner

in-vivo,

NA,

mice

eff↑, TumCG↓, Hif1a↓, PDH↑, lactateProd↓, TumVol↓, TumW↓, Glycolysis↑, neuroP↑,

970-

MET,

Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer

CAFs/TAFs↝, p‑AMPK↑, PHDs↑, Hif1a↓, TumCI↓,

2386-

MET,

Mechanisms of metformin inhibiting cancer invasion and migration

Review,

Var,

OS↑, AMPK↑, EMT↓, TGF-β↓, mTOR↓, P70S6K↓, PKM2↓, Hif1a↓, ChemoSen↑,

2378-

MET,

Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway

in-vitro,

SCC,

CAL27

0, 2.5, 5, 10, 20, 40, 80 and 160 mM) for 24 h

in-vivo,

NA,

Xenograft mouse

TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,

2376-

MET,

Metformin Inhibits Epithelial-to-Mesenchymal Transition of Keloid Fibroblasts via the HIF-1α/PKM2 Signaling Pathway

in-vitro,

Nor,

10, 15, 20 mM

*Hif1a↓, *EMT↓, *p‑P70S6K↓, *PKM2↓,

2375-

MET,

Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling

in-vitro,

GC,

SGC-7901

0-50mM

tumCV↓, TumCI↓, TumCMig↓, Apoptosis↑, PARP↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, COX2↓,

2371-

MET,

The role of pyruvate kinase M2 in anticancer therapeutic treatments

Review,

Var,

ChemoSen↑, PKM2↓, Hif1a↓, EMT↓,

1066-

MET,

Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma

in-vitro,

SCC,

PDH↑, Hif1a↓, TumCMig↓, Casp3↑, P53∅,

Showing Research Papers: 1 to 9 of 9

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 9

Pathway results for Effect on Cancer / Diseased Cells:

Functional Outcomes ⓘ

neuroP↑, 1, OS↑, 1, TumVol↓, 1, TumW↓, 1,
Total Targets: 53

Pathway results for Effect on Normal Cells:

Core Metabolism/Glycolysis ⓘ

PKM2↓, 1,

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1, p‑P70S6K↓, 1,

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,
Total Targets: 4

Scientific Paper Hit Count for: Hif1a, HIF1α/HIF1a

9 Metformin
1 Caffeic acid
1 Dichloroacetate
1 Bortezomib

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:11  Target#:143  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

Metformin / Hif1a Cancer Research Results

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Transcription & Epigenetics ⓘ

DNA Damage & Repair ⓘ

Cell Cycle & Senescence ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Barriers & Transport ⓘ

Immune & Inflammatory Signaling ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Pathway results for Effect on Normal Cells:

Core Metabolism/Glycolysis ⓘ

Proliferation, Differentiation & Cell State ⓘ

Angiogenesis & Vasculature ⓘ

Home Page